Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | August 5, 2020 | News story | Research and Development |Â Â COVID-19, Weekly round up, coronavirusÂ
The coronavirus news this week is dominated by vaccine development, as the UK Government sealed another deal to procure an effective vaccine for its citizens, partnering up with Sanofi and GlaxoSmithKline to reserve 60 million doses of their potential prophylactic candidate currently in development, while the EU has reached an agreement with Sanofi for 300 million doses of their COVID-19 vaccine candidate.
In other COVID-19 news, two new coronavirus tests are set to be made available throughout England that are significantly faster than most already in use.
UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccine – Published on 29/07/20
The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi and GlaxoSmithKline to reserve 60 million doses of their potential prophylactic candidate currently in development.
England to start using two new 90-minute COVID-19 tests in preparation for the winter – Published on 03/08/20
Two new coronavirus tests are set to be made available throughout England that are significantly faster than most already in use.
EU agrees deal with Sanofi for COVID-19 vaccine supply – Published on 03/08/20
The EU has reached an agreement with Sanofi for 300 million doses of their COVID-19 vaccine candidate which will allow the trading bloc’s members to purchase the vaccines if and when it gets an approval.
US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate – Published on 03/08/20
The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the value of $2.1 billion, as part of its Operation Warp Speed to identify, fund and deliver an effective COVID-19 vaccine from a range of promising candidates.
Yale-backed study to test efficacy of AI-selected therapy in COVID-19 – Published on 28/07/20
Biopharma firm AI Therapeutics is partnering with Yale School of Medicine to launch a new clinical trial to identify the efficacy of a drug selected using artificial intelligence (AI) in the treatment of COVID-19 infection.
Conor Kavanagh
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
